Roxadustat for Patients with Posttransplant Anemia: A Narrative Review

Background: Hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) are novel oral agents used for renal anemia treatment. Roxadustat, a first-in-class HIF-PHI used for treating anemia in chronic kidney disease patients, has been approved in China, Japan, South Korea, Chile, and Europe. Ro...

Full description

Bibliographic Details
Published in:	Kidney Diseases
Main Authors:	Xiaoxiao Tang, Fei Liu, Qiuyu Li, Jianhua Mao
Format:	Article
Language:	English
Published:	Karger Publishers 2023-11-01
Subjects:	roxadustat hypoxia-inducible factor renal transplantation anemia
Online Access:	https://beta.karger.com/Article/FullText/535071

Similar Items

Roxadustat: Not just for anemia
by: Xiaoyu Zhu, et al.
Published: (2022-08-01)

The role of roxadustat in chronic kidney disease patients complicated with anemia
by: Jie Liu, et al.
Published: (2023-03-01)

Research progress on roxadustat treatment for renal anemia
by: HU Bao-li, HU Bin
Published: (2022-09-01)

Randomized Study on the Efficacy of Standard Versus Low Roxadustat Dose for Anemia in Patients on Peritoneal Dialysis
by: Zhikai Yang, et al.
Published: (2022-03-01)

Roxadustat for the Treatment of Early Post-Transplantation Anemia
by: Louis Guenal, et al.
Published: (2025-10-01)

Roxadustat on Renal Anemia with Macroinflammation: A Retrospective Cohort Study
by: Yan Tu, et al.
Published: (2024-03-01)

Roxadustat in CKD and transplant patients: A new era in anemia management
by: Muhammad Tassaduq Khan, et al.
Published: (2025-03-01)

Research advances of roxadustat in the treatment of various diseases
by: Tian Qian-qian, et al.
Published: (2022-07-01)

Case report: Roxadustat overdose in an anemia patient of chronic kidney disease: insight beyond insignificant consequence
by: Long-Guang Zhang, et al.
Published: (2024-08-01)

Roxadustat: Do we know all the answers?
by: Qiu-Yu Li, et al.
Published: (2023-05-01)

Influencing factors of clinical efficacy of roxadustat among hemodialysis patients
by: Wenhui Wu, et al.
Published: (2024-12-01)

Thyroid function analysis after roxadustat or erythropoietin treatment in patients with renal anemia: a cohort study
by: Xiaomeng Zheng, et al.
Published: (2023-12-01)

Roxadustat promotes allograft recovery after kidney transplantation: A prospective, multicenter, randomized controlled trial
by: Mao-Lin Ma, et al.
Published: (2025-08-01)

The Efficacy and Safety of Roxadustat for the Treatment of Posttransplantation Anemia: A Randomized Study
by: Weiwei Kong, et al.
Published: (2024-06-01)

Issues on clinical application of hypoxia-inducible factor prolyl hydroxylase inhibitor Roxadustat
by: TU Yan, et al.
Published: (2020-01-01)

Effectiveness and Safety of Roxadustat for Renal Anemia in Dialysis-dependent Chronic Kidney Disease: a Meta-analysis
by: LI Jiaqing, YANG Qing, YUAN Dunlu, HUANG Jingjing, CHANG Qing, NIE Jingwen, ZHOU Zhu, LI Qing
Published: (2023-02-01)

A Case Report of Hypothyrotropin Hypothyroidism Caused by Roxadustat
by: YAN Xuelian, et al.
Published: (2025-03-01)

Roxadustat for ESA‐Hyporesponsive Renal Anemia in a 13‐Year‐Old on Hemodialysis: Case Report and Mini‐Review
by: Meng Zhang, et al.
Published: (2025-10-01)

A retrospective study on the efficacy of Roxadustat in peritoneal dialysis patients with erythropoietin hyporesponsiveness
by: Jie Liu, et al.
Published: (2024-05-01)

Roxadustat for the treatment of anemia in patients with chronic kidney disease: a Meta-analysis
by: WANG Rui, et al.
Published: (2019-01-01)

The Effect of Roxadustat on Transfusion-Dependent Myelodysplastic Syndrome Complicated by Chronic Kidney Disease
by: Ryujiro Hara, et al.
Published: (2021-11-01)

Effect of roxadustat on lowering blood lipids in peritoneal dialysis patients with anemia
by: Tian Xu, et al.
Published: (2025-12-01)

Impact of roxadustat on anemia management in infected patients undergoing long-term dialysis: a retrospective cohort analysis
by: Lulu Wang, et al.
Published: (2025-10-01)

The efficacy and safety of roxadustat for anemia in patients with dialysis-dependent chronic kidney disease: a systematic review and meta-analysis
by: Qiaoqiao Zhou, et al.
Published: (2023-12-01)

Short-term effect of low-dose roxadustat combined with erythropoiesis-stimulating agent treatment for erythropoietin-resistant anemia in patients undergoing maintenance hemodialysis
by: Qiaoying Xu, et al.
Published: (2024-07-01)

Roxadustat attenuates brain injury in mice with heat stroke by regulating mitochondrial fission and fusion
by: 10.16016/j.2097-0927.202405009, et al.
Published: (2024-10-01)

Clinical efficacy and safety analysis in initial hemodialysis patient with renal anemia treated by roxadustat or recombinant human erythropoietin
by: Zhang Peng-jie, et al.
Published: (2022-11-01)

Randomized Trial of Lower-Dose Roxadustat Efficacy and Safety in Non–Dialysis-Dependent CKD-Associated Anemia
by: Ping Li, et al.
Published: (2025-04-01)

The Efficacy and Safety of Roxadustat for Anemia in Hemodialysis Patients with Chronic Kidney Disease: A Meta-Analysis of Randomized Controlled Trials
by: Yunling Geng, et al.
Published: (2024-11-01)

Treatment of anemia of chronic kidney disease caused by ANCA associated vasculitis with roxadustat:one case report with a literature review
by: Xiao Xiang, et al.
Published: (2021-01-01)

Safety of Roxadustat in Chronic Kidney Disease Patients: An Updated Systematic Review and Meta-Analysis
by: Patricia Martínez-Miguel, et al.
Published: (2025-10-01)

A Pharmacodynamic Evaluation of the Protective Effects of Roxadustat Against Hypoxic Injury at High Altitude
by: Guo Q, et al.
Published: (2023-01-01)

The Efficacy and Safety of Roxadustat for Anemia in Patients With Chronic Kidney Disease: A Meta-Analysis
by: Lijun Wang, et al.
Published: (2022-04-01)

Effects of Roxadustat on Erythropoietin Production in the Rat Body
by: Yukiko Yasuoka, et al.
Published: (2022-02-01)

Treatment of pure red cell aplasia in a chronic kidney disease patient with roxadustat: A case report
by: Liu Shanlin, et al.
Published: (2025-10-01)

Roxadustat has risks of reversible central hypothyroidism in patients undergoing hemodialysis: a single-center retrospective cohort study
by: Emiko Otsuka, et al.
Published: (2024-12-01)

The Roxadustat (FG-4592) ameliorates tubulointerstitial fibrosis by promoting intact FGF23 cleavage
by: Jing Wang, et al.
Published: (2025-04-01)

Effects of roxadustat on anemia, iron metabolism, and lipid metabolism in patients with non-dialysis chronic kidney disease
by: Keiji Hirai, et al.
Published: (2023-02-01)

Risk of infection in roxadustat treatment for anemia in patients with chronic kidney disease: A systematic review with meta-analysis and trial sequential analysis
by: Shan Chong, et al.
Published: (2022-09-01)

Low cholesterol levels are good markers for central hypothyroidism in case with dialysis using roxadustat
by: Serina Kita, et al.
Published: (2024-09-01)